Drug intelligence / Profile preview

bortezomib + prednisone

Development stage: Unknown
Lead developer: Janssen Pharmaceutical
Modality: Small Molecules
Administration: Intravenous, Subcutaneous, Oral

Overview

Bortezomib + prednisone is a combination therapy used primarily for the treatment of multiple myeloma. Bortezomib is a proteasome inhibitor that works by inhibiting the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells. Prednisone is a corticosteroid that helps reduce inflammation and suppress immune responses. This combination is often used with melphalan in what's known as the VMP regimen (Velcade, Melphalan, and Prednisone), particularly in elderly patients who are not eligible for high-dose therapy with stem cell transplantation.

Targets

GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)

Beyond the preview

Go deeper on bortezomib + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bortezomib + prednisone.

Explore the full profile